EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Pharmacological Characterization, and Molecular Docking of Minimalist Peptidomimetic Antagonists of α4β1 Integrin

Monica Baiula iD, Michele Anselmi, Francesco Musiani iD, Alessia Ghidini iD, Jacopo Carbone iD, Alberto Caligiana iD, Andrea Maurizio, Santi Spampinato, Luca Gentilucci iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24119588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Monica Baiula und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Peptidomimetics, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Universities and Research, Cassa di Risparmio in Bologna, Ministry of Education, University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrin receptors mediate cell–cell interactions via the recognition of cell-adhesion glycoproteins, as well as via the interactions of cells with proteins of the extracellular matrix, and upon activation they transduce signals bi-directionally across the cell membrane. In the case of injury, infection, or inflammation, integrins of β2 and α4 families participate in the recruitment of leukocytes, a multi-step process initiated by the capturing of rolling leukocytes and terminated by their extravasation. In particular, α4β1 integrin is deeply involved in leukocyte firm adhesion preceding extravasation. Besides its well-known role in inflammatory diseases, α4β1 integrin is also involved in cancer, being expressed in various tumors and showing an important role in cancer formation and spreading. Hence, targeting this integrin represents an opportunity for the treatment of inflammatory disorders, some autoimmune diseases, and cancer. In this context, taking inspiration from the recognition motives of α4β1 integrin with its natural ligands FN and VCAM-1, we designed minimalist α/β hybrid peptide ligands, with our approach being associated with a retro strategy. These modifications are expected to improve the compounds’ stability and bioavailability. As it turned out, some of the ligands were found to be antagonists, being able to inhibit the adhesion of integrin-expressing cells to plates coated with the natural ligands without inducing any conformational switch and any activation of intracellular signaling pathways. An original model structure of the receptor was generated using protein–protein docking to evaluate the bioactive conformations of the antagonists via molecular docking. Since the experimental structure of α4β1 integrin is still unknown, the simulations might also shed light on the interactions between the receptor and its native protein ligands.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidomimeticsNeoplasmsHumansIntegrin alpha4beta1Receptors, Lymphocyte HomingMolecular Docking SimulationIntegrin beta1LigandsIntegrinsCell AdhesionVascular Cell Adhesion Molecule-1

Stichwörter der Autor:innen

VLA-4antagonistsinflammationleukocytesmolecular modellingpeptidomimetics

Substanzen

Integrin alpha4beta1Receptors, Lymphocyte HomingPeptidomimeticsIntegrin beta1LigandsIntegrinsVascular Cell Adhesion Molecule-1

Autor:innen und Institutionen

  • Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
  • Department of Chemistry "G. Ciamician", University of Bologna, Via Selmi 2, 40126 Bologna, Italy.
  • Laboratory of Bioinorganic Chemistry, Department of Pharmacy and Biotechnology, University of Bologna, Viale Fanin 40, 40126 Bologna, Italy.
  • Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.
  • Health Sciences & Technologies (HST) CIRI, University of Bologna, 40064 Ozzano Emilia, Italy.

ORCID-Profile: Monica Baiula, Francesco Musiani, Alessia Ghidini, Jacopo Carbone, Alberto Caligiana, Luca Gentilucci

Förderung

  • Ministry of Education, Universities and Research
  • Cassa di Risparmio in Bologna
  • Ministry of Education, University and Research
  • Department of Excellence Program
  • Fondazione CarisBo

Zitieren

APA

Baiula, M., Anselmi, M., Musiani, F., Ghidini, A., Carbone, J., Caligiana, A., Maurizio, A., Spampinato, S., & Gentilucci, L. (2023). Design, Pharmacological Characterization, and Molecular Docking of Minimalist Peptidomimetic Antagonists of α4β1 Integrin. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119588

Vancouver

Baiula M, Anselmi M, Musiani F, Ghidini A, Carbone J, Caligiana A, et al. Design, Pharmacological Characterization, and Molecular Docking of Minimalist Peptidomimetic Antagonists of α4β1 Integrin. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119588

BibTeX
@article{Baiula2023,
  author = {Baiula, Monica and Anselmi, Michele and Musiani, Francesco and Ghidini, Alessia and Carbone, Jacopo and Caligiana, Alberto and Maurizio, Andrea and Spampinato, Santi and Gentilucci, Luca},
  title = {Design, Pharmacological Characterization, and Molecular Docking of Minimalist Peptidomimetic Antagonists of α4β1 Integrin},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24119588}
}
Kostenlos starten →